[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-wound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-wound":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,86,118,143,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100605490","smart-bandage-with-telemonitoring-vs-standard-care-for-venous-leg-ulcer-randomized-trial-100605490",false,"NCT07163195","Smart Bandage With Telemonitoring vs Standard Care for Venous Leg Ulcer: Randomized Trial","Smart Bandage With App-Based Telemonitoring vs Standard Care for Venous Leg Ulcer: Randomized Trial","SMART-VLU","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Clinically diagnosed venous leg ulcer persisting for more than 3 weeks\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Age \\>65 years (elderly patients excluded)\n* Acute or emergency wounds\n* Mixed etiology ulcers with significant arterial involvement\n* Severe comorbid illness such as end-stage renal failure or active malignancy\n* Cognitive impairment preventing informed consent\n* Allergy to dressing materials","ALL","18 Years","65 Years",{"count":21,"type":22},110,"ESTIMATED","INTERVENTIONAL",[25],"NA","Venous leg ulcers (VLUs) are chronic wounds that are often slow to heal and can greatly affect patients' daily lives. This study will evaluate a new \"smart bandage\" that can monitor wound conditions such as pH, temperature, and moisture, and transmit this information to a mobile app for nurses to review. Care can then be adjusted in real time.\n\nThe purpose of this randomized controlled trial is to compare smart bandage plus standard wound care with standard wound care alone. We will assess whether the smart bandage improves healing rates within 12 weeks, shortens time to healing, reduces infection, and improves quality of life in patients with VLUs. About 110 adult participants with VLUs will be enrolled at Clinic Podiatry Care, Purwokerto, Indonesia.",[28,29],"Venous Leg Ulcer (VLU)","Chronic Wound",[31,29,32,33,34,35,36,37,38,39],"Venous Leg Ulcer","Smart Bandage","Telemonitoring","Digital Health","Mobile Application","Wound Care","Wound Healing","Randomized Controlled Trial","Indonesia","NOT_YET_RECRUITING","2026-06-03",{"date":43,"type":44},"2026-06-04","ACTUAL",{"date":46,"type":22},"2026-07-26",{"date":48,"type":22},"2027-01-27",{"name":50,"class":51},"Asmat Burhan","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":52},"100634554","paw-hydrogel-for-chronic-wound-healing-100634554","NCT07541196","PAW-Hydrogel for Chronic Wound Healing","Efficacy and Safety of a Carbopol® 940 Hydrogel Functionalized With Plasma-Activated Water (PAW) in the Treatment of Chronic Wounds: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Diagnosis of chronic wound (diabetic foot ulcer Wagner grade 1-2, pressure injury grade I-III, dehiscent surgical wound, venous or arterial ulcer) with duration \\> 3 months.\n* Wound surface area between 2 cm² and 20 cm².\n* For diabetic patients: HbA1c \\\u003C 9% (stable metabolic control).\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Clinical or radiological evidence of osteomyelitis (Wagner grade \\> 3).\n* Severe arterial insufficiency (ankle-brachial index \\\u003C 0.5).\n* Use of systemic corticosteroids or immunosuppressants.\n* Pregnancy or lactation.\n* Known autoimmune skin disease (e.g., pemphigus, epidermolysis bullosa).\n* Active malignancy or undergoing chemotherapy\u002Fradiotherapy.\n* Participation in another interventional clinical trial within 30 days prior to screening.",{"count":61,"type":22},50,[25],"The goal of this randomized controlled trial is to evaluate the efficacy and safety of a novel hydrogel made of Carbopol® 940 functionalized with Plasma-Activated Water (PAW) in patients with chronic wounds (diabetic foot ulcers, pressure injuries, dehiscent wounds, arterial and venous ulcers). The main questions it aims to answer are:\n\n* Does PAW-hydrogel accelerate wound closure (reduction in surface area) compared to standard advanced wound care?\n* Does PAW-hydrogel reduce bacterial load in the wound bed?\n* Is PAW-hydrogel safe and well-tolerated (local adverse events, pain)?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group: Topical application of PAW-hydrogel (Carbopol® 940 neutralized to pH 5.5, loaded with reactive oxygen and nitrogen species from plasma activation) 2-3 times per week.\n* Control group: Standard advanced wound care (cleaning, debridement, conventional dressings).\n\nWound area (planimetry), bacterial load (semi-quantitative cultures), pain (Visual Analog Scale), tissue quality (Bates-Jensen scale), and adverse events will be assessed over a 12-week follow-up period.",[65,66,67,31,68,29],"Diabetic Foot Ulcer (DFU)","Pressure Ulcer (PU)","Wound Dehiscence","Arterial Ulcer",[70,71,72,73,74,37,75],"Plasma-Activated Water","PAW","Hydrogel","Chronic Wounds","Diabetic Foot","RONS","RECRUITING","2026-04-14",{"date":79,"type":44},"2026-04-21",{"date":81,"type":22},"2026-04-20",{"date":83,"type":22},"2027-07-30",{"name":85,"class":51},"Benjamín Gonzalo Rodríguez Méndez",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100623418","phase-1-evaluation-of-elu42-topical-spray-for-the-treatment-of-diabetic-foot-ulcers-100623418","NCT07396376","Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers","Protocol ELU42 01 01: Phase I\u002FIIA, Open Label, Single Arm Evaluation of Topical ELU42 (XAV939 in DHA77) for Wagner Grade 1-2 Diabetic Foot Ulcers","Inclusion Criteria:\n\n* Age 18 to ≤75 years;\n* Diagnosis of type 1 or type 2 diabetes mellitus;\n* A1C ≤ 10 (historical within 2 months accepted);\n* BMI ≤ 36;\n* Index DFU Wagner grade 1-2 with post debridement area ≥1.0 cm2 and ≤8.0 cm2;\n* Index DFU present for 4-52 weeks;\n* Index ulcer ≥1 cm below malleoli;\n* Adequate perfusion per ABI\u002FTcPO2\u002FPVR\u002FTBI or Doppler; plantar ulcers off loaded ≥14 days prior to treatment;\n* Ability to consent and attend visits;\n* Contraception requirements for females of childbearing potential.\n\nExclusion Criteria:\n\n* Infected index ulcer or surrounding cellulitis;\n* Ischemic ulcers; osteomyelitis or exposed bone;\n* Recent systemic antibiotic requirement for active infection (eligibility after resolution and 7 day washout);\n* Acute\u002Finactive Charcot preventing off loading; hemoglobin \\\u003C 10 g\u002FdL (unless Sponsor approves);\n* ESRD requiring dialysis;\n* Recent\u002Fplanned vascular procedure on target leg within 30 days;\n* Participation in other IP trials within 30 days;\n* Active alcohol\u002Fsubstance abuse within 3 months;\n* Pregnancy or lactation;\n* Other PI judged exclusions","75 Years",{"count":95,"type":22},15,[97,98],"PHASE1","PHASE2","ELU42 01 01 (SuperHealer42) is a Phase I\u002FIIA open label study sponsored by Eluciderm, Inc. that evaluates the safety and preliminary effectiveness of ELU42, a topical small molecule designed to modulate Wnt signaling, for the treatment of chronic diabetic foot ulcers (DFU). ELU42 combines a tankyrase inhibitor (XAV939) with a novel derivatized hyaluronic acid excipient (DHA77) and is applied as a topical spray to the index ulcer.\n\nFifteen adults with Wagner grade 1-2 diabetic foot ulcers that have been present for at least 4 weeks and up to 52 weeks will be enrolled across up to four U.S. clinical sites. After a 2 week run in period during which standard of care (SOC) is provided (off loading, dressings, and debridement), subjects will receive ELU42 applied on site by trained study staff or the investigator three times per week (Monday, Wednesday, Friday) for six weeks (up to 18 applications). Subjects will be followed weekly during treatment and for up to 6 weeks after the final dose; additional Healing Confirmation visits are scheduled if the wound closes to evaluate the subjects over a course of a 3 month period.\n\nThe study's co-primary objectives are to assess safety (incidence and severity of adverse events and infections) and to measure percent area reduction (PAR) of the index ulcer at Weeks 4 and 6. Efficacy assessments will be performed by the site investigator using direct two axis planimetry and by automated evaluation using the Tissue Analytics platform (surface area, volume, and PAR). Secondary and exploratory assessments include patient reported outcomes (Wound Q and SF 36), frequency of complete wound healing, wound hydration metrics, and pharmacokinetic sampling in a subset of subjects.\n\nContact information for potential participants and referring clinicians is available at each participating site.",[101,102,29,103],"Diabetic Foot Ulcer","Wagner Grade 1 - 2","Open Wound",[105,29,106,103,37],"Wagner 1 and 2 Ulcer","DFU","2026-02-10",{"date":109,"type":44},"2026-02-12",{"date":111,"type":44},"2025-11-10",{"date":113,"type":22},"2026-06-01",{"name":115,"class":116},"Eluciderm Inc","INDUSTRY",4,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":52},"100611028","a-rct-of-moist-ag-dressing-in-chronic-wound-100611028","NCT07235254","A RCT of Moist Ag Dressing in Chronic Wound","Dry Versus Moist Ag Dressings for Local Wound Infections: A Randomized Controlled Trial on Effectiveness and Cost-Effectiveness","Inclusion Criteria:\n\n1. The patient's age ranges from 18 to 80 years old.\n2. According to the IWII wound infection staging, infected wounds are classified as local infections\\*.\n3. The wound type is ulcer, with an ulcer area ranging from 1 to 40 cm².\n4. The wound stage is in the necrosis stabilization phase, granulation growth phase, or epithelial crawling phase\\*\\*.\n5. Voluntary participation in this study and signing the informed consent form\n\nExclusion Criteria:\n\n1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;\n2. The blood sugar level of diabetes is out of control, with fasting blood sugar \\> 15 mmol\u002FL and glycosylated hemoglobin ≥ 10%;\n3. There is active bleeding in the wound, and the conventional basic treatment plan cannot be implemented;\n4. Serum albumin \\\u003C 20 g\u002FL; hemoglobin \\\u003C 60 g\u002FL; platelets \\\u003C 50 × 109\u002FL;\n5. Disseminated infection or systemic infection state, and antibiotics are being used or will be used for treatment;\n6. Patients with advanced malignant tumors;\n7. The patient is in the active stage of autoimmune diseases;\n8. The patient has previously been allergic to self-adhesive soft polysilicone silver ion foam dressings (Meipikang Silver) or Anxidean Nano Silver Trauma Patch;\n9. The patient cannot cooperate or has a mental disorder;\n10. According to the investigator's judgment, the subject has clear reasons that affect wound healing and is not suitable for this study or cannot comply with the requirements of this study.","80 Years",{"count":127,"type":22},40,[25],"This study aims to explore the differences in efficacy and cost-effectiveness between self-adhesive soft polysilicone silver ion foam dressings and traditional silver dressings in local infected wounds through a prospective randomized controlled study. The goal is to provide evidence-based medical support for clinical application, further shorten the wound healing time, and reduce the economic burden on the medical system and patients.",[29,131,132,133,37],"Hard to Heal Wounds","Dressing","Wound he'a'Ling","2025-11-14",{"date":136,"type":44},"2025-11-19",{"date":138,"type":22},"2025-12-01",{"date":140,"type":22},"2027-09-01",{"name":142,"class":51},"Peking University Third Hospital",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":52},"100430638","exciflex-for-chronic-wound-therapy-100430638","NCT04887688","Exciflex for Chronic Wound Therapy","Toward Smart Personalized Electrotherapy for Enhanced Healing of Ischemic Wounds","Inclusion Criteria:\n\n* All participants with chronic ischemic wounds treated at LSCVAMC will be potentially eligible for the study\n* Primary target populations will include Veterans with SCI who are inpatients or residents of the on-site Long-Term Care Unit and Veterans with diabetes being followed by the Podiatry Service for wound care\n\nExclusion Criteria:\n\nIn addition to meeting the general inclusion criteria noted above, further exclusion criteria relating to clinical factors include:\n\n* Age less than 18 years.\n* Pregnancy",{"count":151,"type":22},16,[25],"Objectives: The study objective is to carry a pilot clinical assessment comparing the exciflex bandage to standard of care (SoC) for ischemic wounds and will involve participants who are Veterans with lower extremity ischemic wounds.\n\nResearch Plan: The study will employ a randomized repeated measures design to assess the therapeutic effectiveness of exciflex in clinical use.\n\nMethodology: All participants with chronic ischemic wounds treated at LSCDVAMC will be potentially eligible for the study. Primary target populations will include Veterans with SCI who are inpatients or residents of the on-site Long Term Care Unit and Veterans with diabetes being followed by the Podiatry Service for wound care. In addition to meeting the general inclusion criteria noted above, further exclusion criteria relating to clinical factors include; (1)Age less than 18 years and (2)Pregnancy.\n\nClinical Significance: Chronic ischemic wounds fail to heal normally and are a major challenge in the long-term care of many Veterans. The exciflex bandage can improve outcomes and lower cost by automatically delivering electrotherapy without disturbing the wound dressing for up to seven days, unless indicated. The overall study goal is to complete pre-market testing and evaluation of the exciflex bandage system.",[29,155,156,157],"Diabetes","Spinal Cord Injury","Ischemic Wound","2025-09-04",{"date":160,"type":44},"2025-09-11",{"date":162,"type":44},"2022-10-05",{"date":164,"type":22},"2029-09-30",{"name":166,"class":167},"VA Office of Research and Development","FED",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100586125","exploring-the-effectiveness-of-unpowered-negative-pressure-wound-therapy-100586125","NCT06911307","Exploring the Effectiveness of Unpowered Negative Pressure Wound Therapy","Exploring the Effectiveness of Unpowered Negative Pressure Wound Therapy: a Randomized Controlled Trial","NPWT","Inclusion Criteria:\n\n1. Patients with acute wounds (wound duration \\\u003C4 weeks) or chronic wounds (wound duration ≥4 weeks).\n2. Wound depth \\\u003C2 cm.\n3. Age ≥18 years.\n4. Patients who have been evaluated and approved for participation by their attending physician.\n\nExclusion Criteria:\n\n1. Patients with unstable vital signs.\n2. Presence of ischemia in the wound or surrounding tissues.\n3. Fragile skin around the wound.\n4. Severe wound infection or necrotic tissue.\n5. Wound size \\>10 × 20 cm.",{"count":177,"type":22},160,[25],"The aim of this study is to investigate the effectiveness of Non-powered Negative Pressure Wound Therapy (NPWT) on the healing of abdominal surgical wounds. It is designed as a randomized controlled trial with an experimental group (using NPWT) and a control group (conventional wound care). The study aims to recruit 160 participants: 80 with acute wounds and 80 with chronic wounds. Participants will be randomly assigned to either the experimental group (40 acute wounds, 40 chronic wounds) or the control group (40 acute wounds, 40 chronic wounds). The study will assess wound healing rates and speed, quality of life, self-perceived health status, pain levels, complications, and wound care costs using indicators. Effectiveness will be analyzed using Generalized Estimating Equations (GEE). The study anticipates that results will contribute to evaluating the effects of Non-powered NPWT on wound healing, quality of life, pain, and cost-effectiveness in patients with acute and chronic wounds.",[29,181],"Acute Wound",[183,184,185],"Negative Pressure Wound Therapy;","wound care","randomized controlled trial","2025-03-28",{"date":188,"type":44},"2025-04-04",{"date":190,"type":22},"2025-05-01",{"date":192,"type":22},"2026-03-31",{"name":194,"class":51},"Taipei Medical University"]